Егор Кугно

Pharmaceutical Drug Registration: How AI Cuts Dossier Preparation Time by 60–80% in 2026

The registration dossier for an innovative medicinal product can run anywhere from 100,000 to 500,000 pages. No human team can realistically verify every figure for contradictions, cross-check dosages across sections, or ensure consistent terminology at that scale.

In 2026, algorithms take over the routine. Specialists focus on the decisions that actually require judgment.

January 2026 marked the convergence of two shifts: the close of the EAEU — Eurasian Economic Union transition period for technical regulations, and the global rollout of eCTD — electronic Common Technical Document version 4.0. In December 2025, the EMA opened optional use of version 4.0 for centralized procedures; Japan made the format mandatory for new applications from 2026. In this environment, asking «Will AI replace the regulatory manager?» misses the point. The practical question is: how do you use neural networks to accelerate workflows without losing quality?

Before: Manual Assembly and Weeks of Verification

Before the mass adoption of specialized platforms, preparing a registration dossier in CTD — Common Technical Document format worked like this:
1. A team of medical writers gathered data from fragmented sources.
2. Quality specialists manually reconciled specifications.
3. Translators prepared documents for EAEU member states.

    Each stage took days or weeks.

    Module 1 (Administrative Information) required extracting data from GMP — Good Manufacturing Practice certificates, powers of attorney, and licenses across multiple jurisdictions. Module 2 (Summaries) meant analyzing thousands of pages of non-clinical and clinical reports from Modules 4 and 5 to synthesize conclusions for regulatory reviewers.

    Table 1: Typical Timeline for Dossier Preparation Without AI

    StageTime (without AI)
    Module 1 Assembly5–7 business days
    Clinical Summary Preparation15–20 business days
    Technical Cross-Check for Contradictions3–5 business days
    Translation into 3 EAEU Languages30 business days

    The error margin remained high. If page 1,500 listed «5 mg» while page 45,200 listed «5.0 mg,» a regulatory reviewer could return the dossier for rework. A single such return can delay Marketing Authorization (MA) by months.

    After: Automated Routine and Checks in Minutes

    In 2024–2025, the largest regulatory system providers — Veeva, IQVIA, ArisGlobal, Ennov — integrated AI capabilities into their platforms. By 2026, these tools moved from «experimental» to «standard» for companies operating across multiple jurisdictions.

    Modules 1 and 2: Automation

    Specialized language models trained on medical and regulatory data now handle tasks that previously required a team of five to seven people.
    For Module 1, AI automatically extracts data from certificates, powers of attorney, and licenses. The system recognizes document structures from different EAEU and EU countries, accounting for national language and formatting requirements.
    For Module 2, the RAG (Retrieval-Augmented Generation) architecture is applied. The system loads raw clinical study reports from Module 5 into a vector database. When generating the efficacy section, the model retrieves relevant fragments from CSRs (Clinical Study Reports) covering primary and secondary endpoints. The LLM generates coherent text following ICH E3 guidelines and automatically inserts hyperlinks to Module 5 sources — a task that used to be its own labor-intensive step. Preparing an expert-quality summary now takes 1–2 days instead of 3–4 weeks.

    QC — Quality Control and Discrepancy Detection

    The central problem when submitting to any regulator worldwide — Roszdravnadzor, EMA, or FDA — is technical errors and contradictions between sections.
    AI validators cross-check dosages in the SmPC — Summary of Product Characteristics against specifications (Module 3) and clinical trial reports (Module 5). When the system finds a discrepancy between «5 mg» in one section and «5.0 mg» in another, it flags it as a potential rejection trigger.
    Traditional validators checked only XML schema compliance. New AI validators perform semantic checking, trained on rejection databases from FDA and EMA gateways. The system can predict a rejection not because of a code error, but because of a content anomaly: for example, if section 3.2.S.2 «Manufacture» omits a synthesis description that the application type requires.
    This depth of pre-submission analysis reduces the risk of information requests. According to industry experts, AI-driven validation lowers dossier defect rates by 20–40% and shortens the time to submission readiness.

    The Active Dossier Concept

    In 2026, treating dossier assembly as a one-time event is becoming obsolete. The Active Dossier concept replaces it. Instead of a static snapshot of documents, the system maintains the dossier in a live state. AI agents track document status within the QMS — Quality Management System. As soon as an updated specification is approved in the QMS, an agent automatically initiates a new sequence in the RIM — Regulatory Information Management system and notifies the responsible officer.

    Regulatory Intelligence

    The regulatory environment shifts constantly. In 2025, updated technical schemas for electronic document structures came into force (EEC — Eurasian Economic Commission Board Decision No. 67 of 19 April 2022). From April 2026, Japan transitions to eCTD 4.0; the EMA plans a mandatory transition for centrally authorized products by 2027.
    AI agents monitor updates on the EEC, Ministry of Health of the Russian Federation, EMA, and FDA portals. The system generates actionable recommendations mapped to the company’s portfolio: «EEC Decision No. XXX has been published. Stability sections must be updated within 90 days for Group Y products.»

    EAEU Specifics and Gap Analysis

    For EAEU countries, 2026 is a turning point. The transition period has closed, and pharmaceutical companies now face mass dossier realignment against Union requirements. Manually scanning thousands of dossiers against new pharmacopoeial monographs is not feasible.
    Specialized AI gap analysis tools address this. An algorithm scans an existing national dossier, semantically compares its content against current EAEU requirements, and generates a report on missing documents or non-compliances. The system can identify the absence of a bioequivalence study conducted under the new Union rules, or a discrepancy between impurity specifications and the harmonized pharmacopoeia.
    The EAEU also presents a multilingual challenge. Neural machine translation (NMT) trained on biomedical vocabulary automates translation of administrative data and SmPCs from Russian into the state languages of member countries — Kazakh, Armenian, Belarusian, Kyrgyz. Modern systems integrate Translation Memory (TM), maintaining terminological consistency across an entire product portfolio.

    Table 2: Dossier Preparation Timeline — Traditional vs. AI-Assisted (2026)

    StageWithout AIWith AI (2026)
    Module 1 Assembly5–7 business days2–4 hours
    Clinical Summary (Module 2)15–20 business days2–3 business days
    Technical Dossier Cross-Check3–5 business days15–30 minutes
    Translation (3 EAEU languages)30 business days2 business days (incl. human review)

    The Regulatory Specialist’s Toolkit in 2026

    Specialized RIM Platforms

    RIM — Regulatory Information Management systems have become standard for mid-to-large pharma. Market leaders — Veeva Vault RIM, IQVIA RIM Smart, ArisGlobal LifeSphere — offer built-in AI for submission planning, eCTD package generation and validation, global registration tracking, and dossier change management.
    These systems support eCTD 3.2.2 (the current standard) and are preparing for the shift to eCTD 4.0, which moves from a document-centric to a data-centric model.
    One aspect of eCTD 4.0 deserves attention: Controlled Vocabularies. Unlike version 3.2.2, which allowed free-text entry in many fields, version 4.0 requires precise codes — for example, code C42998 instead of the word «Tablet.» Generative AI models often struggle to reproduce codes with full accuracy, so neuro-symbolic systems have become the standard. The generative component (LLM) interprets user intent («we are registering a film-coated tablet»), while the symbolic component (Rules Engine) queries the NCI or EUTCT database for the valid code. This reduces validation errors to near zero.

    Language Models for Regulatory Tasks

    Public models — ChatGPT, Claude, Gemini — are unsuitable for confidential dossiers. Processing new molecule data through a public neural network constitutes a privacy violation and a trade secrets risk.
    Large pharma companies use closed (on-premise) AI environments or specialized models trained on medical data. These models adhere to MedDRA — Medical Dictionary for Regulatory Activities terminology, do not hallucinate on medical questions, and are fine-tuned to the requirements of specific regulators. Translation of registration documentation into EAEU member languages — Kazakh, Armenian, Kyrgyz — requires both linguistic precision and strict eCTD structure preservation simultaneously. Specialized translation systems handle this combination and reduce translation time by a factor of 10–15 compared with manual work.

    Ethical and Legal Barriers

    One principle holds firm across 2026: for errors in a dossier prepared with AI assistance, the QP — Qualified Person (the company’s authorized officer) bears responsibility. The AI developer does not.
    Regulators do not accept «algorithmic error» as grounds for rejection appeals. All AI outputs must pass verification by a qualified specialist. AI accelerates the routine; it does not reassign accountability.

    Data Confidentiality

    Registration dossier work involves proprietary information: new molecule data, clinical trial results, manufacturing processes. Public language model versions cannot be used for these tasks.
    Companies must use only on-premise solutions or cloud services with data isolation guarantees, execute NDAs with AI solution providers, and audit systems for GxP compliance.

    Regulatory Requirements for AI

    In January 2026, the FDA and EMA published joint Guiding Principles of Good AI Practice in Drug Development. Three points directly affect dossier preparation:

    Human-centricity. AI cannot be the final arbiter. Any system’s architecture must include mandatory human involvement in decision-making. The «Submit» button is always pressed by a human.
    Data management. Full traceability of training data is required. If AI generates a summary, the sponsor must be able to demonstrate which specific clinical data informed that conclusion.
    Risk-based approach. The validation level for an AI tool must match the risk level of the process. Generating a label that affects patient safety requires stricter model validation than sorting incoming correspondence.

    The Hallucination Problem

    Generative models produce plausible but false information — a problem with real consequences in regulatory work. In 2025, lawyers in the US were sanctioned for citing non-existent case law generated by ChatGPT. In the regulatory sphere, a fabricated safety profile can cost lives.
    Current systems include Confidence Scoring mechanisms. When AI generates a statement with low correlation to the source text, the fragment is flagged for mandatory manual review. Legal responsibility for eCTD content rests entirely with the Marketing Authorization holder, regardless of whether the text was written by a human or a machine.

    eCTD 4.0 and New AI Capabilities

    The shift in eCTD 4.0 is a move from a rigid folder structure to a dynamic XML/JSON-based message structure. Instead of «leaf» elements, metadata is primary. Version 4.0 is built on the HL7 Regulated Product Submission (RPS) standard, where the primary unit is data and its context of use — the document becomes secondary.
    One concrete innovation: Object Reuse. Each document receives a unique UUID, allowing it to be referenced across different procedures without re-uploading. Tracking thousands of UUIDs over a product’s decades-long lifecycle is an impossible cognitive load for humans. For algorithms, it is trivial, making them indispensable for maintaining dossier integrity.
    eCTD 4.0 also introduces built-in two-way communication between the applicant and the regulator. This creates a need for intelligent agents that can classify incoming regulatory queries in real time, assess urgency, and route them to the appropriate experts.
    The new format opens up content reuse across different applications, automatic data aggregation, and machine processing without PDF parsing. AI systems perform best with structured data. Companies that prepare now — deploying unified RIM systems and structuring master data — gain a head start when the transition becomes mandatory.

    What to Do Now

    Audit current processes. Measure the time your team spends on dossier assembly, cross-checking, and translation. Identify where automation delivers the highest return.
    Select the right platform. Companies with global portfolios need comprehensive RIM systems — Veeva or IQVIA. Local manufacturers may find simpler AI-enabled solutions adequate.
    Protect confidentiality. Public AI tools cannot be used for registration documentation. Require data isolation guarantees and GxP compliance from any vendor.
    Prepare for eCTD 4.0. Even if your markets do not yet require the new format, begin structuring master data and building data governance processes now.
    Upskill the team. Knowing the regulatory framework is no longer enough. Regulatory specialists need digital literacy: understanding how algorithms work, critical thinking to evaluate AI output, and the ability to formulate system queries. Knowledge of XML syntax matters less than prompt engineering and algorithmic auditing.

    Table 3: Regulatory Process Evolution with AI

    ProcessTraditional ApproachAI-Assisted (2026)Efficiency Gain
    Regulatory IntelligenceManual monitoring of agency websitesAI agents scan databases 24/7, map changes to portfolioReal-time
    Module 1 AssemblyManual data entry into forms, high error riskAuto-fill from RIM/LIMS, auto-selection of controlled vocabularies~70% time saved
    Module 2 AuthoringWriters draft from scratch — weeksGenAI (RAG) generates draft; writer edits~50% time saved
    QC and ValidationManual checks, technical validation onlyQC bots, semantic validation, predictive analysis~80% time saved
    Translation (EAEU)Agency outsourcing, inconsistent terminologySpecialized NMT with Translation Memory~60% cost saved

    In 2026, AI does not replace the specialist’s judgment — it removes the drudgery. The «self-writing dossier» remains a work in progress: the «Submit» button is always pressed by a human, and the Human-in-the-Loop principle ensures this remains the case. Dossier preparation — categorization, summarization, formatting, and validation — is now 60–80% algorithmic. The specialist decides what to submit. AI handles how it is packaged. Companies that build these workflows ahead of the curve gain an advantage in speed to market.

    Sources: Guiding Principles of Good AI Practice in Drug Development (FDA/EMA, January 2026); EEC Council Decision No. 78 of 3 November 2016 «On Rules for Registration and Examination of Medicinal Products for Medical Use»; EEC Board Decision No. 67 of 19 April 2022 «On Updating Technical Schemas for Electronic Document Structures»; EEC Board Decision No. 79 of 30 June 2017 «On Requirements for Electronic Forms of Regulatory Dossier Applications and Documents.»

    Other articles on Regulatory Affairs →

    This page in Russian →